nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.12.2004

Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake

verfasst von: Montserrat Estorch, Ignasi Carrió, Esther Mena, Albert Flotats, Valle Camacho, Jordi Fuertes, Jaume Kulisewsky, Jagat Narula

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Imaging with metaiodobenzylguanidine (MIBG) is used for the assessment of neuronal dysfunction in various cardiovascular disorders. Although valuable information is obtained by resting MIBG imaging, it is conceivable that competitive interference with the re-uptake mechanism would exaggerate MIBG defects and might unmask subclinical neuronal dysfunction. Tricyclic antidepressants, such as amitriptyline, have been reported to significantly increase cardiac MIBG washout and inhibit uptake into presynaptic neurons. This study was undertaken to assess whether a single oral dose of amitriptyline could influence cardiac MIBG distribution.

Methods

Six patients (aged 62–81 years; four males, two females) who had demonstrated a normal cardiac MIBG scan during work-up for movement disorders were studied. The patients underwent a second ¹²³I-MIBG study after oral administration of 25 mg amitriptyline within 1 week. Single-photon emission computed tomography images were acquired at 4 h to assess the regional distribution of MIBG, after generation of polar maps and employing a 20-segment model. Mean percentage of peak activity was calculated for each segment at rest and after amitriptyline administration.

Results

After amitriptyline administration, there was a decrease in regional MIBG uptake in 10±4 segments per patient [62/120 segments (52%): 37 segments with a 5–10% decrease, 25 segments with a >10% decrease]. This change was statistically significant in lateral (P=0.003), apical (P<0.0001) and inferior (P=0.03) regions.

Conclusion

A single oral dose of amitriptyline can induce changes in the uptake and retention of cardiac MIBG, indicating the feasibility of use of pharmacological intervention in cardiac neurotransmission imaging.

Dae MW, O’Connell J, Botvinick EH, et al. Scintigraphic assessment of regional cardiac innervation. Circulation 1989; 79:634–644.

Sisson JC, Wieland DM, Sherman P, Mangner MC, Tobes MC, Jacques S. Metaiodobenzylguanidine as an index of adrenergic nervous system integrity and function. J Nucl Med 1987; 28:1620–1624.PubMed

Sisson JC, Bolgos G, Jhonson J. Measuring acute changes in adrenergic nerve activity of the heart in the living animal. Am Heart J 1991; 121:1119–1123.CrossRefPubMed

Knickmeier M, Matheja P, Wichter T, et al. Clinical evaluation of no-carrier-added meta-(¹²³I)iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med 2000; 3:302–307.CrossRef

Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471–477.PubMed

Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40:917–923.PubMed

Maunoury C, Agostini D, Acar P, et al. Impairment of cardiac neuronal function in childhood dilated cardiomyopathy: an I123-MIBG scintigraphic study. J Nucl Med 2000; 41:400–404.PubMed

Udelson J, Shafer C, Carrió I. Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management. J Nucl Cardiol 2002; 5:S40–S52.CrossRef

Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001; 42:1062–1076.PubMed

10.

Taki J, Nakajima K, Hwang EH, et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000; 27:566–573.CrossRefPubMed

11.

Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000; 41:71–77.PubMed

12.

Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonogral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155:60–67.CrossRefPubMed

13.

American Society of Nuclear Cardiology. Imaging guidelines for nuclear cardiology procedures, Part 2. J Nucl Cardiol 1999; 6:G47–G84.PubMed

14.

Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry 1981; 38:1160–1180.PubMed

15.

Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry 2003; 64 Suppl 13:13–17.

16.

Malizia AL, Melichar JK, Rhodes CG, Haida A, Reynolds AH, Jones T, Nutt DJ. Desipramine binding to noradrenaline reuptake sites in cardiac sympathetic neurons in man in vivo. Eur J Pharmacol 2000; 391:263–267.CrossRefPubMed

17.

AHFS (American Hospital Formulary Service). Drug information (1990): antidepressants. In: McEvoy G, ed. AHFS drug information. Bethesda, MD: American Society of Hospital Pharmacists; 1990:1160–1161.

18.

Hollister LE. Tricyclic antidepressants. N Engl J Med 1978; 23:1168–1172.

19.

Preskorn SH, Irwin HA. Toxicity of tricyclic antidepressants: kinetics, mechanism, intervention. J Clin Psychiatry 1982; 43:151–156.PubMed

20.

Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry 2003; 64 Suppl 13:13–17.

21.

Huangfu D, Goodwin WB, Guyenet PG. Sympatholytic effect of tricyclic antidepressants: site and mechanism of action in anesthetized rats. Am J Physiol 1995; 268:R1429–R1441.PubMed

22.

Buckley NA, Chevalier S, Leditschke IA, et al. The limited utility of electrocardiography variables used to predict arrhythmia in psychotropic drug overdose. Crit Care 2003; 5:349–350.

23.

Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14:230–240.PubMed

24.

Tsuchimochi S, Tamaki N, Tadamura E, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med 1995; 6:969–974.

25.

Estorch M, Carrió I, Berná Ll, Lopez J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine uptake relates to age. J Nucl Cardiol 1995; 2:126–132.PubMed

26.

Gill JS, Hunter GJ, Gane G, Gamm AJ. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy. Am Heart J 1993; 2:390–398.

27.

Kiyono Y, Iida Y, Kawashima H, et al. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging 2002; 8:888–1005.

28.

Gerson MC, Craft LL, McGuire N, Suresh DP, Abraham WT, Wagoner LE. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by¹²³I-metaiodobenzylguanidine. J Nucl Cardiol 2002; 9:608–615.CrossRefPubMed

29.

Toyama T, Hoshizaki H, Seki R, et al. Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol activity. J Nucl Med 2003; 44:1604–1611.PubMed

30.

Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy—clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001; 141:645–652.CrossRefPubMed

Titel: Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake
verfasst von: Montserrat Estorch
Ignasi Carrió
Esther Mena
Albert Flotats
Valle Camacho
Jordi Fuertes
Jaume Kulisewsky
Jagat Narula
Publikationsdatum: 01.12.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1520-2

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2004

Reply

Prognostic value of fatty acid imaging in patients with angina pectoris without prior myocardial infarction: comparison with stress thallium imaging

Waiting for Godot: waiting in nuclear medicine

High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy

Relation between wall thickening on gated perfusion SPECT and functional recovery after coronary revascularization in patients with previous myocardial infarction

December 2004